A Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults

J Drugs Dermatol. 2023 Aug 1;22(8):761-765. doi: 10.36849/jdd.7481.ABSTRACTPsoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque psoriasis. With proven efficacy and safety, topical corticosteroids are often used, although adverse effects and limitations for use exist. Tapinarof (Vtama®), a novel topical aryl hydrocarbon receptor modulating drug, was approved by the US Food and Drug Administration for the treatment of plaque psoriasis in adults in May 2022. A literature search of PubMed, MEDLINE, and ClinicalTrials.gov was conducted using the following keywords: tapinarof, psoriasis, GSK2894512. Articles published before January 2023 were included in this review. This review describes the preclinical and clinical studies demonstrating the efficacy and safety of tapinarof, its place in therapy, and relevance to patient care. Kalabalik-Hoganson J, Nogid A, Frey K. A review of tapinarof: novel topical treatment for plaque psoriasis in adults. J Drugs Dermatol. 2023;22(8):761-765. doi:10.36849/JDD.7481.PMID:37556516 | DOI:10.36849/jdd.7481
Source: Journal of Drugs in Dermatology - Category: Dermatology Authors: Source Type: research